Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes With Novel Approaches to Targeted Therapy

Learn about novel approaches to targeted therapy in the treatment of patients with relapsed/refractory DLBCL with this on-demand webcast and downloadable slides from a live Grand Rounds series.

Share

Program Content

Activities

R/R DLBCL
Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes with Novel Approaches to Targeted Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 23, 2023

Activities

Therapeutic Advances in RR DLBCL
Therapeutic Advances in Relapsed/Refractory DLBCL: Improving Outcomes With Novel Approaches to Targeted Therapy
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 21, 2023

Expires: August 20, 2024

Faculty

cover img faculity

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Provided by

ProCE Banner
ProCE Banner

Jointly provided by USF Health and Rockpointe.

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc